Evidence map›Paper›PMID 31448924›Full record

ArticleMolecular pharmaceutics2019

Effect of Particle Formation Process on Characteristics and Aerosol Performance of Respirable Protein Powders.

Ashlee D Brunaugh, Tian Wu, Sekhar R Kanapuram, Hugh D C Smyth

Abstract read
In one paragraph

Article in Molecular pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Dry Powder Inhalers for Delivery of Synthetic Biomolecules.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  6. Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ashlee D BrunaughCollege of Pharmacy , The University of Texas at Austin , 2409 West University Avenue, PHR 4.214 , Austin , Texas 78712 , United States.ORCID 0000-0001-5456-5427
Tian WuAmgen , One Amgen Center Drive , Thousand Oaks , California 91320 , United States.
Sekhar R KanapuramAmgen , One Amgen Center Drive , Thousand Oaks , California 91320 , United States.
Hugh D C SmythCollege of Pharmacy , The University of Texas at Austin , 2409 West University Avenue, PHR 4.214 , Austin , Texas 78712 , United States.ORCID 0000-0002-3261-466X

Funding

Optimization of next generation pulmonary dry powder delivery systemsF31HL146178 · NHLBI · UNIVERSITY OF TEXAS AT AUSTIN · PI BRUNAUGH, ASHLEE D · 2019 to 2020
$64k
NHLBI NIH HHS F31 HL146178
6 · The paper itself

Abstract

Pulmonary delivery of biopharmaceuticals may enable targeted local therapeutic effect and noninvasive systemic administration. Dry powder inhaler (DPI) delivery is an established patient-friendly approach for delivering large molecules to the lungs; however, the complexities of balancing protein stability with aerosol performance require that the design space of biopharmaceutical DPI formulations is rigorously explored. Utilizing four rationally selected formulations obtained using identical atomization conditions, an extensive study of the effect of the particle formation process (spray drying or spray freeze-drying) on powder properties, aerosol performance, and protein stability was performed. Multiple linear regression analysis was used to understand the relationship between powder properties, device dispersion mechanism, and aerosol performance. Spray drying and spray freeze-drying, despite the same spraying conditions, produced powders with vastly different physical characteristics, though similar aerosol performance. The resulting regression model points to the significance of particle size, density, and surface properties on the resulting aerosol performance, with these factors weighing differently according to the device dispersion mechanism utilized (shear-based or impaction-based). The physical properties of the produced spray dried and spray freeze-dried powders have differing implications for long-term stability, which will be explored extensively in a future study.

Indexed as

Drug CompoundingDry Powder InhalersAdministration, InhalationAerosolsDesiccationFreeze DryingHumansMannitolMuramidaseNanoparticlesPowdersProtein StabilitySucroseAerosolsMannitolMuramidasePowdersSucrosebiopharmaceuticaldispersibilityparticle engineeringpulmonary drug deliveryspray dryingspray freeze-drying

Identifiers

PMID31448924
PMCPMC6800019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.